MISITATUG BLIVEDOTIN
UNII NS5GTS5FLQ

Substance Identification & Data

This profile provides standardized clinical and technical data for Misitatug Blivedotin, uniquely identified by the FDA Unique Ingredient Identifier (UNII) NS5GTS5FLQ.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2767203-06-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

NS5GTS5FLQ

CAS Registry Number

2767203-06-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

MISITATUG BLIVEDOTIN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C174395

National Cancer Institute reference terminology for clinical and research data.

INN ID

12877

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Misitatug Blivedotin

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Misitatug Blivedotin. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Misitatug Blivedotin

Common Names & Synonyms

H-gamma1 heavy chain (1-454) [VH Musmus/Homsap (Mus musculus IGHV4-1*02 (91.8%) -(IGHD) -IGHJ1*01 (100%)/Homo sapiens IGHV3-74*03 (80.6%) Q120>A (116), M123>T (119) -(IGHD) -IGHJ3*01 (85.7%), CDR-IMGT [8.8.17] (26-33.51-58.97-113)) (1-124) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1 R120>K (221) (125-222), hinge 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-213')-disulfide with Lkappa light chain (1'-213') [V-KAPPA Musmus/Homsap (Mus musculus IGKV4-55*01 (84.0%) -IGKJ1*01 (90.9%) L124>V (103)/Homo sapiens IGKV6-21*02 (68.4%) -IGKJ4*01 (100%), CDR-IMGT [5.3.9] (27'-31'.49'-51'.88'-96')) (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152'), V101 (190') (107'-213')]; dimer (233-233'':236-236'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa; substituted at the sulfur atoms of four L-cysteinyl residues on an average among 227, 233, 236, 213', 227'', 233'', 236'' and 213''' with two divalent radical groups consisting of 3,3'-[(2S,3R,6R,7R,82S,11R,12S,15S,18S,26S,29S)-12-[(2S)-butan-2-yl]-26-[3-(carbamoylamino)propyl]-2-hydroxy-7,11-dimethoxy-3,6,13,19-tetramethyl-5,9,14,17,20,25,28,31,36-nonaoxo-15,18,29-tri(propan-2-yl)-21-oxa-33-thia-4,13,16,19,24,27,30-heptaaza-37(1)-[1,3,5]triazinana-8(2,1)-pyrrolidina-1(1),23(1,4)-dibenzenaheptatriacontaphane-373,375-diyl]bis(3-oxopropyl) (blivedotin)

Immunoglobulin G1, anti-(human mesothelin) (human-Mus musculus monoclonal RC88 γ1-chain), disulfide with human-Mus musculus monoclonal RC88 κ-chain, dimer, reduced, cyclic bis(thioether) with N-methyl-N-[[[4-[[N-[2-[[3-oxo-3-[tetrahydro-3,5-bis(3-mercapto-1-oxopropyl)-1,3,5-triazin-1(2H)-yl]propyl]thio]acetyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide

immunoglobulin G1-kappa, anti-[Homo sapiens MSLN (mesothelin, pre-pro-megakaryocyte-potentiating factor, megakaryocyte-potentiating factor, MPF, CAK1)]; conjugated on an average of 4 cysteinyl residues to monomethylauristatin E (MMAE), with a ratio of 1 to 2, via a cleavable divalent linker

misitatug blivedotin [INN]

External Clinical & Regulatory Resources

Previous UNIINS5B428UKN

Next UNIINS60A490T1